Business Valuation

Initial Public Offering (IPO)

Congratulations to SinoMab BioScience Limited (stock code: 3681.HK) on its successful listing on the main board of HKSE on 12 November 2019. With regard to this listing application, AVISTA Group is honored to be engaged in providing valuation in relation to the equity incentive plan of the company.   
 
<img src="../../../../../uploads/sinomab_eng_2efe33d182.jpeg" width="700" />

Congratulations to SinoMab BioScience Ltd. (Stock Code: 3681.HK) on its Successful Listing

Congratulations to GL-Carlink Technology Holding Limited (2531.HK) on its successful listing on the Mainboard of HKSE on 15 July 2024.
GL-Carlink Technology Holding Limited (“GL-Carlink Technology”) is an in-vehicle hardware and SaaS marketing and management service provider for players within the automotive aftermarket industry in China, with a focus on (i) sales of in-vehicle hardware products; and (ii) provision of SaaS marketing and management services, covering SaaS subscription services and SaaS value-added services, to the industry participants along the industry value chain.
 
GL-Carlink Technology is dedicated to supporting our customers in the automotive aftermarket industry to better connect with their customers through our sales of in-vehicle hardware products and SaaS marketing and management services, which formed part of our SaaS value-added services. With decade-long operational experience and coupled with our industry insight and an ability to leverage the capability of technology GL-Carlink Technology have developed industry-specific products and services for industry participants along the automotive aftermarket industry value chain such as 4S stores to improve their marketing and operational efficiencies.
 
With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to financial assets for financial reporting purpose and valuation service on total equity value for internal reference.
 
Congratulations again to GL-Carlink Technology Holding Limited (2531.HK) on its successful listing. The issue price is HKD 4.70 per share and the amount of funds raised is HKD 230 million.
 
<img src="../../../../../uploads/Slide1_79eadb12af.png" width="500" />

103193696_l_normal_none.png

Congratulations to GL-Carlink Technology Holding Limited (2531.HK) on its Successful Listing

Congratulations to Shanghai Voicecomm Information Technology Co., Ltd.(2495.HK) on its successful listing on the Mainboard of HKSE on 10 July 2024.
 
Shanghai Voicecomm Information Technology Co., Ltd.(“ Voicecomm”) provides audio and video communication hardware and software solutions to enterprise customers in the People’s Republic of China. It offers Voicecomm Suites, which covers various steps of enterprise-level users’ end-to-end information exchanges and business interactions; and Voicecomm Brain that connects stably to enterprise-level users’ various types of operating systems. It also provides software and information technology services. The company serves end-customer industries, including city management and administration, automotive and transportation, telecommunication, finance, education, healthcare, tourism, media, e-commerce, retailing, etc.
 
With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to financial instruments, financial assets, purchase price allocation and goodwill impairment test.
 
Congratulations again to Shanghai Voicecomm Information Technology Co., Ltd.(2495.HK) on its successful listing. The issue price is HKD152.10 per share and the amount of funds raised is HKD 664 million.
 
<img src="../../../../../uploads/Slide1_6a907f8006.png" width="500" />

96560573_l_normal_none.png

Congratulations to Shanghai Voicecomm Information Technology Co., Ltd.(2495.HK) on its Successful Listing

Congratulations to Jiangxi Rimag Group Co.,Ltd. (2522.HK) on its successful listing on the Mainboard of HKSE on 7 June 2024.
 
Jiangxi Rimag Group Co.,Ltd. (“Rimag”) , a prominent medical group in China specializing in medical imaging, is the sole operator and manager of a comprehensive medical imaging platform offering diverse services and value across the entire industry chain in China. Rimag mainly compete in the PRC third-party medical imaging center market, a fast-growing segment whose market size grew at a CAGR of 29.0% from 2018 to 2023 and is expected to grow with a CAGR of 33.5% from 2023 to 2026, far exceeding that of 12.9% and 14.3% of the PRC medical imaging service market during the same periods, respectively.
 
With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to preferred shares, employee stock plan, M&amp;A transactions, financial assets, goodwill and asset impairment tests and expected credit losses.
 
Congratulations again to Jiangxi Rimag Group Co.,Ltd. (2522.HK) on its successful listing. The issue price is HKD14.98 per share and the amount of funds raised is HKD266.88 million.
 
<img src="../../../../../uploads/Slide1_63a76fa60f.png" width="500" />